Fig. 2

pAXLxCD3ε in vitro T cell re-directed cytotoxic activity. A Graphical representation of pAXLxCD3ε structure and mechanism of action. B Relative percentage (%) of mediated killing- represented as % of 7AAD negative and AXL positive cells (SKOV3, ES-2,OVCAR-8 and EFO-21) and AXL negative (RMG-I) ovarian cancer cell lines co-cultured with PBMC from healthy donor at E:T ratio 10:1 in the presence of increasing concentrations (0.1 μg/ml, 1 μg/ml and 2.5 μg/ml) of pAXLxCD3ε or vehicle, 72 h after treatment. C Relative % of T cell mediated killing on ES-2 cells co-cultured with healthy donor-derived PBMC at E:T ratio 10:1 in the presence of increasing concentrations of pAXLxCD3ε (0.1 μg/ml, 1 μg/ml and 2.5 μg/ml) or negative control (pBCMAxCD3ε 2.5 μg/ml) 72 h after treatment. D Viability measured as bioluminescence value of ES-2 LUC cells co-cultured with PBMC from healthy donor at E:T ratio 10:1 in presence of vehicle or increasing concentrations of pAXLxCD3ε (0.1 μg/ml, 1 μg/ml and 2.5 μg/ml) 72 h after treatment. E Representative immunofluorescence microscopy image of EOC spheroids (Red) co-cultured with healthy donor PBMC (green) at E:T ratio 10:1 and treated with vehicle or pAXLxCD3ε 2.5 μg/ml. F Cell viability measured as absorbance at OD (optical density 450 nm) of EOC cells treated with increasing concentrations of pAXLxCD3ε (0.1 μg/ml, 1 μg/ml and 2.5 μg/ml) in the absence of effector cells. Student’s t-test was applied to calculate statistical significance *p < 0.05, **p < 0.01, ***p < 0.001